Maria Gonzalez

4.4k citations

53 papers · 1.7k indexed · 1 hit paper · h-index 15

Oncology top 2%
- Cancer Immunotherapy and Biomarkers 28
- CAR-T cell therapy research 18
- Cutaneous Melanoma Detection and Management 18
Genetics top 5%
Pulmonary and Respiratory Medicine top 5%
- Brain Metastases and Treatment 9
Immunology top 10%
- Immunotherapy and Immune Responses 5
Molecular Biology
- Melanoma and MAPK Pathways 14
Organic Chemistry
- Click Chemistry and Applications 4
Computational Theory and Mathematics
- Computational Drug Discovery Methods 3

Co-authors: Georgina V. Long Alexander M. Menzies Serigne Lo Richard A. Scolyer Shahneen Sandhu Michael P. Brown Grant A. McArthur Alexander Guminski
Cited by: Oncology Genetics Pulmonary and Respiratory Medicine
Journals: Cell (1 paper)Nature Medicine (2 papers)Journal of Clinical Oncology (24 papers)
Partner nations: Australia Netherlands Sweden

In The Last Decade

Maria Gonzalez

49 papers receiving 1.6k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Maria Gonzalez

Since Specialization

Citations

This map shows the geographic impact of Maria Gonzalez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Gonzalez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Gonzalez more than expected).

Fields of papers citing papers by Maria Gonzalez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Gonzalez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Gonzalez. The network helps show where Maria Gonzalez may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Maria Gonzalez, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Maria Gonzalez Line = papers co-authored together Maria Gonzalez links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study The Lancet Oncology ·Georgina V. Long,Victoria Atkinson,Serigne Lo,Alexander Guminski,Shahneen Sandhu,Michael P. Brown,Maria Gonzalez,Grant A. McArthur,Alexander M Menzies	2025	9
2	Tumor-infiltrating lymphocyte expansion protocols for adoptive cell therapy in cancer Cellular Oncology ·Daniel Tovar Manzano,Nabil Subhi‐Issa,Alejandro Pereiro-Rodríguez,Igor Gregorio López Cade,Maria Gonzalez,Miguel Fernández‐Arquero,Pedro Pérez Segura,Cristina Ujaldón Miró,Silvia Sánchez‐Ramón,Alberto Ocaña,María Guzmán Fulgencio	2025	0
3	FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma. Journal of Clinical Oncology ·Li Zhou,Edward Hsiao,Serigne Lo,Matteo S. Carlino,George Au‐Yeung,Maria Gonzalez,Andrew J. Spillane,Thomas E. Pennington,Julie R. Howle,Kerwin F. Shannon,Rony Kapoor,Jonathan R. Stretch,David Gyorki,Robyn P.M. Saw,Sydney Ch’ng,Richard A. Scolyer,Georgina V. Long,Alexander M. Menzies	2024	0
4	A phase I trial of intratumoral STX-001: A novel self-replicating mRNA expressing IL-12 alone or with pembrolizumab in advanced solid tumors. Journal of Clinical Oncology ·Jason J. Luke,Laura C. Kennedy,Neil Sankar,Alexander M. Menzies,Alexander Christopher Jonathan Van Akkooi,Maria Gonzalez,Julie Urban,Mini Gill,Cynthia M. Atkins,Julian Quiñones,Brian J. Miller,Alison A. Duhamel,Ryan Sowell,Prashant R. Nambiar,Tasuku Kitada,Sarina A. Piha‐Paul,Kamalesh K. Sankhala,Georgina V. Long	2024	3
5	Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma Annals of Oncology ·Alexander M. Menzies,Serigne Lo,Robyn P.M. Saw,Maria Gonzalez,Sydney Ch’ng,O E Nieweg,Kerwin F. Shannon,P M Ferguson,Jenny Lee,Louise Emmett,R Kapoor,R V Rawson,Jonathan R. Stretch,John F. Thompson,A J Spillane,Helen Rizos,R A Scolyer,Georgina V. Long	2024	8
6	Use of early circulating tumour DNA dynamics in patients with stage III melanoma receiving neoadjuvant combination immunotherapy. Journal of Clinical Oncology ·Wei Yen Chan,Jenny Lee,Ashleigh Stewart,Russell J. Diefenbach,Maria Gonzalez,Alexander M. Menzies,Christian U. Blank,Richard A. Scolyer,Georgina V. Long,Helen Rizos	2024	1
7	A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage I to III resectable Merkel cell carcinoma (Neo-MCC). Journal of Clinical Oncology ·Maria Gonzalez,Alexander Christopher Jonathan Van Akkooi,Sydney Ch’ng,Kerwin F. Shannon,Andrew J. Spillane,Jonathan R. Stretch,Michael Rtshiladze,Thomas E. Pennington,David J. Coker,Robyn P.M. Saw,Rony Kapoor,Edward Hsiao,Robert V. Rawson,Monica Osorio,Alexander M. Menzies,Serigne Lo,Richard A. Scolyer,Angela Hong,Georgina V. Long,Ines Esteves Domingues Pires Da Silva	2024	0
8	Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial Nature Medicine ·Georgina V. Long,Matteo S. Carlino,George Au‐Yeung,Andrew J. Spillane,Kerwin F. Shannon,David Gyorki,Edward Hsiao,Rony Kapoor,Jake Thompson,Iris Batula,Julie R. Howle,Sydney Ch’ng,Maria Gonzalez,Robyn P.M. Saw,Thomas E. Pennington,Serigne Lo,Richard A. Scolyer,Alexander M. Menzies	2024	15
9	The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo. Journal of Clinical Oncology ·Irene L. M. Reijers,Alexander M. Menzies,Judith M. Versluis,Robyn P.M. Saw,Winan J. van Houdt,Ellen Kapiteijn,Astrid Aplonia Maria Van Der Veldt,Karijn P.M. Suijkerbuijk,Hanna Eriksson,Geke A.P. Hospers,W. Martin C. Klop,Marta López‐Yurda,Lindsay G. Grijpink-Ongering,Maria Gonzalez,Andrew J. Spillane,Richard A. Scolyer,Bart A. van de Wiel,Alexander Christopher Jonathan Van Akkooi,Georgina V. Long,Christian U. Blank	2023	6
10	1096P Prolonged follow-up confirms durability of favorable outcomes after neoadjuvant ipilimumab plus nivolumab in melanoma Annals of Oncology ·M.W. Lucas,Elisa A. Rozeman,Judith M. Versluis,Alexander M. Menzies,Hanna Eriksson,B. van de Wiel,Richard A. Scolyer,H.V. van Thienen,Henk Mallo,Maria Gonzalez,L. Landman,A. Torres Acosta,Lindsay G. Grijpink-Ongering,John B.A.G. Haanen,Alexander C. J. van Akkooi,Georgina V. Long,Christian U. Blank	2023	1
11	Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma Nature Medicine ·Itske Fraterman,Irene L. M. Reijers,Petros Dimitriadis,Annegien Broeks,Maria Gonzalez,Alexander M. Menzies,Marta López‐Yurda,Ellen Kapiteijn,Astrid A.M. van der Veldt,Karijn P.M. Suijkerbuijk,Geke A.P. Hospers,Georgina V. Long,Christian U. Blank,Lonneke V. van de Poll‐Franse	2023	22
12	793P NeoPeLe: A phase II trial of neoadjuvant (NAT) pembrolizumab (Pembro) combined with lenvatinib (Lenva) in resectable stage III melanoma Annals of Oncology ·Georgina V. Long,Andrew J. Spillane,Thomas E. Pennington,Kerwin F. Shannon,Jonathan R. Stretch,Maria Gonzalez,R.P.M. Saw,Serigne Lo,Richard A. Scolyer,Alexander M. Menzies	2022	11
13	Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia Cancer Chemotherapy and Pharmacology ·Hannah Yejin Kim,Janna K. Duong,Maria Gonzalez,Georgina V. Long,Alexander M. Menzies,Helen Rizos,Su Yin Lim,Jenny Lee,Alan V. Boddy	2019	15
14	Site‐specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti–PD‐1 therapy Cancer ·Inês Pires da Silva,Serigne Lo,Camelia Quek,Maria Gonzalez,Matteo S. Carlino,Georgina V. Long,Alexander M. Menzies	2019	108
15	OpACIN-neo: A multicenter phase II study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) Annals of Oncology ·Christian U. Blank,Elisa A. Rozeman,Alexander M. Menzies,Bart A. van de Wiel,Chandra Mani Adhikari,Karolina Sikorska,Oscar Krijgsman,Hanna Eriksson,Carolien Bierman,Lindsay G. Grijpink-Ongering,Maria Gonzalez,Annegien Broeks,Alexander Guminski,Andrew J. Spillane,W. Martin C. Klop,Robyn P.M. Saw,Richard A. Scolyer,Alexander C. J. van Akkooi,Johan Hansson,Georgina V. Long	2018	12
16	Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 studybreakdown → The Lancet Oncology ·Georgina V. Long,Victoria Atkinson,Serigne Lo,Shahneen Sandhu,Alexander Guminski,Michael P. Brown,James S. Wilmott,Jarem Edwards,Maria Gonzalez,Richard A. Scolyer,Alexander M. Menzies,Grant A. McArthur	2018	655
17	A Phase II, Randomised, Open Label Study of Neoadjuvant Pembrolizumab with/without Dabrafenib and Trametinib (D+T) in BRAF V600 Mutant Resectable Stage IIIB/C/D Melanoma (NeoTrio Trial) Annals of Oncology ·Maria Gonzalez,Alexander M. Menzies,Robyn P.M. Saw,John F. Thompson,Andrew J. Spillane,Julie R. Howle,Omgo E. Nieweg,Kerwin F. Shannon,Sydney Ch’ng,Jonathan R. Stretch,Matteo S. Carlino,Alexander Guminski,Louise Emmett,Helen Rizos,Richard A. Scolyer,Georgina V. Long	2017	7
18	Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage IIIB/C BRAF V600 mutant melanoma Annals of Oncology ·Alexander M. Menzies,Maria Gonzalez,Alex Guminski,Omgo E. Nieweg,Kerwin F. Shannon,John F. Thompson,Richard Kefford,Sydney Ch’ng,Jonathan R. Stretch,Andrew J. Spillane,J. Lee,H. Lee,Rony Kapoor,Louise Emmett,Helen Rizos,Robyn P.M. Saw,Richard A. Scolyer,Georgina V. Long	2017	29
19	Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage iiib/c BRAF-V600 mutation positive melanoma. Journal of Clinical Oncology ·Robyn P.M. Saw,Alexander M. Menzies,Alexander Guminski,Omgo E. Nieweg,Kerwin F. Shannon,Maria Gonzalez,Sydney Ch’ng,Richard Kefford,John F. Thompson,Jonathan R. Stretch,Andrew J. Spillane,Richard A. Scolyer,Georgina V. Long	2016	7
20	Phase III randomized pilot study comparing interferon alpha- 2b in combination with radiation therapy versus radiation therapy alone in patients with stage III-B carcinoma of the cervix International Journal of Gynecological Cancer ·R Yazigi,G. Aliste,R. Zebadua Torres,Ana María Ciudad,María Concepción González Cuevas,Juan de Dios Sáez Garrido,Silvia Maria Prado,Ana Marija Šola,Rodrigo L. Castillo,Begoña Cerdá,Miguel A. Cumsille,Maria Gonzalez,CONCEPCION NAVARRO,Jose Reyes	2003	10

About Maria Gonzalez

Maria Gonzalez is a scholar working on Oncology, Biological Psychiatry and Molecular Biology, having authored 53 papers that have together received 1.7k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (28 papers), CAR-T cell therapy research (18 papers), Cutaneous Melanoma Detection and Management (18 papers), Melanoma and MAPK Pathways (14 papers), Brain Metastases and Treatment (9 papers), Immunotherapy and Immune Responses (5 papers), Click Chemistry and Applications (4 papers) and Computational Drug Discovery Methods (3 papers). The work is most often cited by research in Oncology (1.1k citations), Genetics (233 citations) and Pulmonary and Respiratory Medicine (544 citations). Maria Gonzalez has collaborated with scholars based in Australia, Netherlands and Sweden. Frequent co-authors include Georgina V. Long, Alexander M. Menzies, Serigne Lo, Richard A. Scolyer, Shahneen Sandhu, Michael P. Brown, Grant A. McArthur, Alexander Guminski, Victoria Atkinson and Jarem Edwards. Their work appears in journals such as Cell, Nature Medicine and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact